BridgeBio Pharma, Inc. (FRA:2CL)
61.64
+0.22 (0.36%)
At close: Nov 28, 2025
BridgeBio Pharma Revenue
BridgeBio Pharma had revenue of $120.70M USD in the quarter ending September 30, 2025, with 4,318.01% growth. This brings the company's revenue in the last twelve months to $353.78M, up 62.46% year-over-year. In the year 2024, BridgeBio Pharma had annual revenue of $221.90M with 2,285.27% growth.
Revenue (ttm)
$353.78M
Revenue Growth
+62.46%
P/S Ratio
39.46
Revenue / Employee
$484.63K
Employees
730
Market Cap
11.90B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 221.90M | 212.60M | 2,285.27% |
| Dec 31, 2023 | 9.30M | -68.35M | -88.02% |
| Dec 31, 2022 | 77.65M | 7.93M | 11.38% |
| Dec 31, 2021 | 69.72M | 61.47M | 745.14% |
| Dec 31, 2020 | 8.25M | -32.31M | -79.66% |
| Dec 31, 2019 | 40.56M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Mercedes-Benz Group AG | 136.97B |
| Bayerische Motoren Werke Aktiengesellschaft | 136.42B |
| Deutsche Telekom AG | 121.02B |
| Allianz SE | 105.02B |
| Siemens Aktiengesellschaft | 78.91B |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.10B |
| Siemens Energy AG | 39.08B |
| SAP SE | 36.49B |
BridgeBio Pharma News
- 6 days ago - BridgeBio to Participate in December Investor Conferences - GlobeNewsWire
- 8 days ago - BridgeBio Pharma: Set For New Commercial Launches After Trial Successes - Seeking Alpha
- 12 days ago - BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 19 days ago - Interesting BBIO Put And Call Options For April 2026 - Nasdaq
- 20 days ago - BridgeBio Pharma (BBIO): Wells Fargo Raises Price Target to $84 | BBIO Stock News - GuruFocus
- 21 days ago - BridgeBio Pharma, Inc. (BBIO) Presents at UBS Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 22 days ago - BridgeBio (BBIO) Reports Promising Data for Acoramidis in Cardiac Study - GuruFocus
- 23 days ago - Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations - GlobeNewsWire